---
title: Electrical Muscle Stimulation with 1064 Nm Diode Laser and RF/PEMF for Non-invasive Body Contouring and Fat Reduction.
nct_id: NCT05256771
overall_status: ACTIVE_NOT_RECRUITING
phase: NA
sponsor: Venus Concept
study_type: INTERVENTIONAL
primary_condition: Fat Reduction
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05256771.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05256771"
ct_last_update_post_date: 2025-03-28
last_seen_at: "2026-05-12T07:21:46.284Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Electrical Muscle Stimulation with 1064 Nm Diode Laser and RF/PEMF for Non-invasive Body Contouring and Fat Reduction.

**Official Title:** Safety and Efficacy of Electrical Muscle Stimulation Combined with 1064 Nm Diode Laser, Pulsed Electromagnetic Field (PEMF) and Vacuum Assisted Radio Frequency (RF) for Non-invasive Body Contouring and Fat Reduction.

**NCT ID:** [NCT05256771](https://clinicaltrials.gov/study/NCT05256771)

## Key Facts

- **Status:** ACTIVE_NOT_RECRUITING
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 36
- **Lead Sponsor:** Venus Concept
- **Conditions:** Fat Reduction, Muscle Tone Increased
- **Start Date:** 2021-11-01
- **Completion Date:** 2025-09-30
- **CT.gov Last Update:** 2025-03-28

## Brief Summary

Multi-center, three-arm, randomized, evaluator-blinded study of electrical muscle stimulation (EMS) and/or 1064 nm diode laser, pulsed electromagnetic field (PEMF) and vacuum assisted radio frequency (RF) using the Venus Bliss Max for fat reduction, body contouring and aesthetic improvement.

## Detailed Description

The study will enroll up to 60 male and female subjects, ≥ 18 years of age, requesting non-invasive electrical muscle stimulation (EMS) and/or lipolysis of the abdomen and flanks. Subjects will be randomized to one of three arms as per randomization scheme.

This study will have 3 Arms at a ratio of 2:1:1 (A:B:C):

Arm A: Full Treatment Arm (Laser + EMS + RF/PEMF) Arm B: EMS/RF Arm (EMS + RF/PEMF) Arm C: EMS Arm (EMS only)

Arm A: Three (3) diode laser treatments treatments at days 0, 28 and 56 (±2 days). Subjects will also receive bi-weekly electrical muscle stimulation and pulsed electromagnetic fields (PEMF)/vacuum assisted radio frequency (RF) treatments at days 0, 14, 28, 42 and 56 (±2 days).

Arm B: Subjects will receive bi-weekly electrical muscle stimulation and pulsed electromagnetic fields/vacuum assisted radio frequency treatments at days 0, 14, 28, 42 and 56 (±2 days).

Arm C: Subjects will receive weekly electrical muscle stimulation treatments at days 0, 7, 14, 21, 28 and 35 (±2 days).

Subjects in Arms A and B will be followed at 84 and 140 days (±7 days) after their last treatment. Subjects in Arm C will be followed at 63 and 119 days (±7 days) after their last treatment.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 65 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

1. Male and female subjects \> 18 years of age and ≤65 years of age.
2. Subject agrees to refrain from any new abdominal training exercises during the course of the study.
3. BMI ≤ 30 kg/m2 as determined at screening.
4. Subject has read and signed a written informed consent form.

Exclusion Criteria:

1. Pregnant in the last 3 months, intending to become pregnant, postpartum or nursing in the last 6 months, including presence of post-partum diastasis.
2. Any previous liposuction/lipo-sculpture or any type of surgical procedure in the treatment area in the past 12 months.
3. History of immunosuppression/immune deficiency disorders (including AIDS and HIV infection) or use of immunosuppressive medications last 6 months prior to and during the course of the study.
4. History of hyperlipidemia, diabetes mellitus, hepatitis, blood coagulopathy or excessive bleeding.
5. Use of antiplatelet medications (81 mg acetylsalicylic acid daily permitted), anticoagulants, thrombolytics or anti-inflammatory medications within 2 weeks of treatment or a history of bleeding disorders.
6. History of skin cancer or any other cancer in the areas to be treated, including presence of malignant or pre-malignant pigmented lesions.
7. Having a permanent implant in the treatment area such as metal plates or an injected chemical substance such as silicone or parenteral gold therapy (gold sodium thiomalate), or drug delivery system that would prevent treatment at the treatment site.
8. Use of medications, herbs, food supplements, and vitamins known to induce photosensitivity to light exposure at the wavelength used or history of photosensitivity disorder.
9. Suffering from significant skin conditions in the treatment area or inflammatory skin conditions including but not limited to open lacerations, abrasions, herpes sores, cold sores, active infections.
10. Tattoos in the treatment area
11. Numbness, tingling or other altered sensation in the treatment area.
12. Known sensitivity or allergy to isopropyl alcohol and propylene glycol, hydrogel or latex or any substance used during treatments by the clinic (if applicable).
13. Unable or unwilling to comply with the study requirements.
14. Enrolled in a clinical study of any other investigational drug or device.
15. Any other condition or laboratory value that would, in the professional opinion of the Investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject.
```

## Arms

- **Arm A: Full Treatment Arm (Laser + EMS + RF/PEMF)** (ACTIVE_COMPARATOR) — Arm A: Three (3) diode laser treatments treatments at days 0, 28 and 56 (±2 days). Subjects will also receive bi-weekly electrical muscle stimulation and pulsed electromagnetic fields/vacuum assisted radio frequency treatments at days 0, 14, 28, 42 and 56 (±2 days).
- **Arm B: EMS/RF Arm (EMS + RF/PEMF)** (ACTIVE_COMPARATOR) — Arm B: Subjects will receive bi-weekly electrical muscle stimulation and pulsed electromagnetic fields/vacuum assisted radio frequency treatments at days 0, 14, 28, 42 and 56 (±2 days).
- **Arm C: EMS Arm (EMS only)** (ACTIVE_COMPARATOR) — Arm C: Subjects will receive weekly electrical muscle stimulation treatments at days 0, 7, 14, 21, 28 and 35 (±2 days).

## Interventions

- **EMS** (DEVICE) — Abdominal muscle stimulation using EMS
- **1064 nm diode laser** (DEVICE) — Adipose tissue heating using 1064 nm diode laser
- **RF/PEMF** (DEVICE) — Collagen re-modelling and reduction in subcutaneous fat using RF/PEMF

## Primary Outcomes

- **Blinded, independent photo review comparing the pre-treatment and post-treatment photographs.** _(time frame: 140 days (Arms A & B); 119 days (Arm C))_ — Physician board-certified dermatologist to evaluate contour improvement per the Global Aesthetic Improvement Scale (GAIS), with scores in order of 'most improved' to 'worse': Most improved (score of 5); Much improved (score of 4); Improved (score of 3); No change (score of 2); Worse (score of 1).

## Secondary Outcomes

- **Blinded Investigator review comparing the pre-treatment photographs and post-treatment Follow-up live assessment.** _(time frame: Follow-up 1: 84 days (Arm A & B); 63 days (Arm C). Follow-up 2: 140 days (Arms A & B); 119 days (Arm C))_
- **Change in the subject Body Satisfaction Questionnaire (BSQ)** _(time frame: Follow-up 1: 84 days (Arm A & B); 63 days (Arm C). Follow-up 2: 140 days (Arms A & B); 119 days (Arm C))_
- **Change in Anthropometric measurements: Abdominal Circumference** _(time frame: Treatment 1 and 3; Day 0 and Day 28 (Arm A and B). Treatment 1 and 5; Day 0 and Day 28 (Arm C). Follow-up 1: 84 days (Arm A & B); 63 days (Arm C). Follow-up 2: 140 days (Arms A & B); 119 days (Arm C))_
- **Change in Anthropometric measurements: Abdominal Skinfold Thickness** _(time frame: Treatment 1; Day 0 (All Arms). Follow-up 1: 84 days (Arm A & B); 63 days (Arm C). Follow-up 2: 140 days (Arms A & B); 119 days (Arm C))_
- **Change in Anthropometric measurements: Weight** _(time frame: Treatment 1; Day 0 (All Arms). Follow-up 1: 84 days (Arm A & B); 63 days (Arm C). Follow-up 2: 140 days (Arms A & B); 119 days (Arm C))_

## Locations (3)

- Scripps Clinical Research - General Medicine, San Diego, California, United States
- Schweiger Dermatology Group, Hackensack, New Jersey, United States
- Tennessee Clinical Research Center, Nashville, Tennessee, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.scripps clinical research - general medicine|san diego|california|united states` — added _(2026-05-12)_
- `locations.schweiger dermatology group|hackensack|new jersey|united states` — added _(2026-05-12)_
- `locations.tennessee clinical research center|nashville|tennessee|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05256771.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05256771*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*